Eli Lilly (NYSE:LLY) announced Wednesday that an executive search is underway to find an internal or external replacement for ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks to watch as Jim Cramer looked at market rationality. Cramer discussed ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

The company says broad tariffs would raise costs, limit patient access and undermine domestic manufacturing. Eli Lilly is sounding a warning on proposed tariffs on pharmaceuticals, saying it would ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

More than 80% of the potential $100 million in tax credits Eli Lilly could receive for its expansion in Kenosha County would ...